SIRP Alpha / CD172a / SIRPA Drug Discovery Landscape & Assay Solutions

  • By admin
  • 30 Jul 2026
  • Comments

Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Checkpoint Inhibitor Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for SIRPA drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen SIRPA ECD-Fc / Polymorphic Variants (V1/V2)
High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation).		 View SIRPA Products
Gene Delivery SIRPA Promise-ORF / Lentivirus
Full-length ORF for stable myeloid cell line construction. Sequence Verified.		 View SIRPA Products
Benchmark Ab Anti-SIRPA (Biosimilar sequence)
Recombinant positive control. High Purity (>95%).		 View SIRPA Products
Validator SIRPA siRNA Set
For knockdown verification and off-target screening.		 View SIRPA Products
Related Target A CD47
The primary ligand; essential for CD47-SIRPA axis disruption assays.		 View CD47 Products
Related Target B CD24
Alternative "don't eat me" signal for synergistic macrophage activation.		 View CD24 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
High Human Polymorphism (V1, V2, etc.) Comprehensive SIRPA variant panel (ECD-Fc). Sequence Verified for exact polymorphic matching.
Glycosylation-dependent Binding HEK293 Expressed (Native Glycosylation) to ensure accurate receptor-ligand interaction profiling.
Lack of Standardized Controls Clinical Benchmark Antibodies (Biosimilars) included with strictly controlled endotoxin levels.
Off-Target False Positives Validated siRNA sets included for precise specificity and background checks in cell-based assays.

Live SIRPA R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for myeloid checkpoint therapeutics is intensifying, with major players shifting focus from direct CD47 blockade to SIRPA-targeted modalities. Direct CD47 targeting often results in severe hemagglutination and anemia due to ubiquitous RBC expression. By targeting SIRPA, which is restricted to myeloid cells (macrophages, dendritic cells, neutrophils), developers can unleash potent tumor phagocytosis while bypassing the RBC antigen sink and mitigating hematological toxicities. As first-generation CD47 therapies face clinical hurdles, the next wave of R&D is heavily focused on anti-SIRPA monoclonal antibodies, SIRPA-Fc decoy fusion proteins, and bispecifics (e.g., Tumor Antigen x SIRPA) designed to bridge macrophages directly to the tumor microenvironment.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Monoclonal Antibody Boehringer Ingelheim, ALX Oncology Solid Tumors, Hematologic Malignancies Affinity & Polymorphism Screening (Need high-purity variant ECD-Fc)
Bispecific (TAA x SIRPA) Various Biotechs Targeted Solid Tumors Heterodimer Validation (Need High-Purity HEK293-expressed Antigens)
Fusion Protein (Decoy) Trillium (Pfizer), ALX Oncology AML, MDS Receptor Blocking Assays (Need Endotoxin <1EU/ug CD47 and SIRPA proteins)